Paras Sharma, Principal at InBC Investment Corp., shared on X:
“ADC field’s uneven maturity:
Diversification in targets, consolidation in payloads.
Title: Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
Authors: Louise Conilh, Virginia Metrangolo, Silvia Crescioli, Janice M. Reichert, Charles Dumontet.
Read The Full Article.”
Alicia D’Souza, Translational Scientist at Valius Sciences, added on X:
“With more ADCs coming on line, we’re going to need to think more about how to sequentialize ADCs.
One of the issues here is exposure to one payload class can confer payload resistance and limit following ADC options for a patient.
I’m excited about companies that are innovating in ADC payload chemistry, especially those using AI to discover new payload classes.”
You may also be interested in: TQB2102 and the Evolution of HER2 Antibody-Drug Conjugates: Exploring the Role of Payload Optimisation in Breast Cancer
